Published Paper Details:

Rheumatoid arthritis (RA) is a systemic autoimmune disease manifested by chronic joint inflammation which causes significant disability and death. RA affects women 3-5 times more than men, with a global frequency of roughly 0.3%-1%. Until now there no known cure for RA; the aim goal of treatment is to reduce symptoms. For the symptomatic relief of the disease therapy strategy entails constant drug delivery at maximum doses. Indomethacin, diclofenac, ibuprofen, celecoxib, and etorcoxib are examples of NSAIDs. These strong medications frequently have side effects. Desired effects, which significantly reduces patient compliance Furthermore, traditional nonsteroidal anti-inflammatory drugs. There are numerous formulation problems, such as limited solubility and permeability, as well as inadequate bioavailability. Gastrointestinal enzyme degradation, dietary interactions, and toxicity Researchers are working to overcome these obstacles. Have gone down the topical route of administration. For the improvement of drug delivery in the RA therapy , a variety of adaptable Nano carriers with controlled physicochemical features, tailorable drug release patterns, or active targeting ability were created. Researchers now selected the topical drug delivery as a means of getting over these obstacles because it has better patient compliance and avoids the initial side effect of conventional oral administration. Furthermore, nanosized carriers like liposomes, nanoemulsions, niosomes, ethosomes, solid lipid nanoparticles, and transferosomes have been developed to improve the drug's ability to permeate through the skin's layers and reach the site of inflammation. These drug delivery methods have a high drug encapsulation efficiency, are non-toxic, and offer prolonged drug release.This review aims to provide an up-to-date progress regarding RA treatment using nanomedicines in the last 5 years and succinctly discuss the potential application of several newly emerged therapeutic strategies, such as fostering pro-resolving therapy, inducing antigen-specific tolerance, or managing immunometabolism for RA treatments.